Natural Alternatives Int L Inc v Iancu
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Prost, Moore, and Reyna. Appeal from the Patent Trial and Appeal Board
Summary: Removing the priority claim of one application in a chain can affect the ability of pending and subsequently filed applications to claim priority to earlier applications.
Natural Alternatives International (“NAI”) filed a series of eight patent applications claiming priority to an original 1997 application. NAI filed the fifth application, which was a continuation-in-part, in 2003 and the sixth application in 2008 while the fifth was still pending. Four days after filing the sixth application, NAI amended the fifth to delete the earlier priority claim, which resulted in a longer patent term for the fifth application. During inter partes reexamination, the examiner and the Board determined the eighth application was entitled only to the priority date of the fifth application because NAI “deliberately and expressly terminated their claim to the priority of the first four applications.”
The Federal Circuit affirmed. The court rejected NAI’s argument that the priority claim in the sixth application “vested” when the application was filed and the fifth application still claimed priority to the first four applications. By amending the priority claim of the fifth application, NAI caused the subsequently filed applications to lack a specific reference to the earlier applications. Accordingly, the eighth application was entitled only to the priority date of the fifth application, and could be rejected in view of the first application. The court also held that NAI could not “have it both ways” by obtaining extended patent term on the fifth application while obtaining the benefit of the earliest priority date for later applications.
This case is: NATURAL ALTERNATIVES INT’L, INC. V. IANCU
Edited by: Paul Stewart
Written by: Brandon G. Smith & Adam Powell
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…